Along with the fact that it will be eligible to earn up to $420 in development, regulatory, and commercial milestone payments to develop the use of this IRAK4 molecule degrader against ...

The deal will focus on first-in-class protein degrader therapies targeting a protein known as IRAK4 – short for interleukin-1 receptor-associated kinase 4. Kymera is set to receive $150m in ...

Researchers at Oregon State University say they have made a "significant breakthrough" in using nanoparticles to deliver ...

Nurix Therapeutics announced that its collaboration partner, Gilead Sciences, will commence a Phase 1 clinical trial for the IRAK4 degrader GS-6791/NX-0479 in healthy volunteers in Q2 2025 ...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Board of ...

2 Trap Falls Road Suite 106, Shelton, CT 06484 USA Ph: +1-203-852-6800, 800-243-6002 ...

“GS-6791/NX-0479 is a highly optimized, selective, oral degrader of IRAK4, a master regulator of IL-1R/TLR signaling pathways that plays a crucial role in inflammatory processes. IRAK4 has both ...

May 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor ...

The company outlined its strategic focus on the IRAK4 program, emphasizing opportunities in hematological malignancies like Non-Hodgkin's Lymphoma (NHL) and Acute Myeloid Leukemia (AML). Curis ...

May 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor ...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Board of ...

"GS-6791/NX-0479 is a highly optimized, selective, oral degrader of IRAK4, a master regulator of IL-1R/TLR signaling pathways that plays a crucial role in inflammatory processes. IRAK4 has both kinase ...